In this Issue:
Radiotherapy, TKIs improve survival in ALK+ NSCLC
Alectinib in ALK+, crizotinib-resistant NSCLC
. . . North American and global clinical evidence
Frozen section guides resection in early lung cancer
CRT vs chemotherapy only in elderly patients with limited-stage SCLC
Low-dose CT screening: no survival benefit in SCLC
TG4010 + chemotherapy promising in advanced NSCLC
Surgery vs CRT boost after induction chemotherapy in stage III NSCLC
Preoperative RT after induction chemotherapy in IIIA/N2 NSCLC
LMWH thromboprophylaxis in lung cancer: no survival benefit
Please login below to download this issue (PDF)